APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H ...
Ezoic announces advancements lifting customer display EPMV by 27% on average while cutting ad load times by a full ...
AccessIT Group today announced it has become a Palo Alto Networks NextWave Platinum Innovator AccessIT Group joins a select group of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results